- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Selpercatinib Elicits Encouraging Antitumor Activity in Pediatric RET-Altered Solid Tumors
June 6th 2021, 6:37pm
Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.
Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant Medullary Thyroid Cancer
June 6th 2021, 6:35pm
Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy.
Nivolumab Plus Chemotherapy Outperforms Chemotherapy Alone in Resectable NSCLC
June 6th 2021, 6:21pm
Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
Adjuvant Gefitinib Fails to Outshine Chemo in EGFR+ NSCLC
June 6th 2021, 6:13pm
Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.
Ultralow Risk 70-Gene Signature Is Indicative of Excellent Survival Outcomes in Early-Stage Breast Cancer
June 6th 2021, 6:10pm
Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated have an excellent survival prognosis regardless of clinical risk.
Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer
June 6th 2021, 6:07pm
The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.
Neoadjuvant Pertuzumab Plus Trastuzumab/Nab-Paclitaxel Achieves 64% pCR With Less Toxicity in HER2+ Breast Cancer
June 6th 2021, 5:51pm
Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.
CART-ddBCMA Elicits 100% ORR in Relapsed/Refractory Multiple Myeloma
June 6th 2021, 5:43pm
The autologous CAR T-cell product CART-ddBCMA was found to elicit a 100% objective response rate in patients with relapsed/refractory multiple myeloma, with deep and durable responses noted in those with poor prognostic factors.
Meaningful Impact on Outcomes Demonstrated with De-Escalation Strategy in HER2+/HR– Breast Cancer
June 6th 2021, 5:34pm
A de-escalated course of neoadjuvant therapy of trastuzumab and pertuzumab with or without added weekly paclitaxel for only 12 weeks yielded high response rates and significant survival in patients with HER2-positive, hormone receptor–negative early breast cancer.
Durvalumab Plus Neoadjuvant Chemotherapy Yields Long-Lasting Survival in Early TNBC
June 6th 2021, 5:23pm
The addition of durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy was found to significantly improve survival in patients with early triple-negative breast cancer.
Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients
June 6th 2021, 4:31pm
Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.
Dr. Tawbi on the Efficacy of Relatlimab/Nivolumab in Advanced Melanoma
June 6th 2021, 4:28pm
Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.
Targeting CLL1-Positive Cells Shows Efficacy in Early Trial in Pediatric AML
June 6th 2021, 3:10pm
Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia.
Tafasitamab/Lenalidomide Combo Induces Durable Response in DLBCL
June 6th 2021, 3:00pm
Three-year follow-up data from the phase 2 L-MIND study demonstrated that tafasitamab-cxix in combination with lenalidomide induces sustainable response in relapsed/refractory diffuse large B-cell lymphoma.
Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato
June 6th 2021, 12:00am
OncLive News Network: On Location at ASCO 2021
OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.
Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors
June 5th 2021, 10:57pm
Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.
Liposomal Irinotecan Combo Improves Outcomes for Patients with Biliary Tract Cancer
June 5th 2021, 10:40pm
Data from the phase 2 NIFTY trial demonstrated that liposomal irinotecan in combination with 5-fluorouracil/leucovorin significantly improved progression-free survival and overall survival for patients with metastatic biliary tract cancer whose disease had progressed following first-line line gemcitabine/cisplatin.
Ribociclib/Fulvestrant Maintains Survival Benefit in Postmenopausal HR+ Advanced Breast Cancer, Irrespective of Setting
June 5th 2021, 10:14pm
Ribociclib plus fulvestrant continued to significantly improve overall survival over fulvestrant alone in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up, irrespective of whether patients received the regimen in the first- or second-line setting.
Frontline Camrelizumab Plus Chemotherapy Improves Survival in Advanced Esophageal Squamous Cell Carcinoma
June 5th 2021, 10:10pm
Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
Venetoclax/Fulvestrant Combo Found to Be Inferior to Fulvestrant Alone in ER+/HER2- Breast Cancer
June 5th 2021, 9:50pm
The combination of venetoclax and fulvestrant failed to improve overall outcomes vs fulvestrant alone in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.